Dioxamate is the anticonvulsant. It was developed as anti-epileptic agent.

Telatinib (Bay-579352) developed by Bayer is an orally available and highly potent inhibitor of tyrosine kinases VEGFR2,VEGFR3, PDGFR and c-Kit. Telatinib is a potent inhibitor of angiogenesis. Telatinib caused a significant decrease in endothelium-dependent and endothelium-independent vasodilation. Telatinib demonstrates anti-tumor activity in various cancer models. Telatinib is ready for phase III clinical trials for the treatment of gastric cancer. In 2010, it has been granted orphan drug status by the FDA. Most frequent adverse events were pain, nausea, voice changes and fatigue.

Talibegron (ZD2079) is a β3 adrenoceptor agonist and insulin sensitiser. It was developed as a potential treatment for obesity and non-insulin-dependent diabetes mellitus. Talibegron hydrochloride had been in phase II clinical trials by AstraZeneca for the treatment of type 2 diabetes and obesity. However, this research has been discontinued.

Spirofylline, theophylline derivative, is a bronchodilator, which can be used to treat asthma and bronchitis and emphysema.

Sulfonterol is a benzenemethanol derivative patented by Smith Kline and French Laboratories as a bronchodilator. Sulfonterol acts as a β-adrenergic partial agonist.

Pirodomast is Thromboxane A (TXA2) synthetase inhibitor. Pirodomast can inhibit leukotriene (LT) D4, C4, E4 formation and Thromboxane B2 (TXB2) activities. It was weak or ineffective as an antagonist of histamine, methacholine, serotonin, LTC4 or platelet activating factor induced bronchospasms in guinea pigs. Also, pirodomast was not a bronchodilator or calcium influx blocker and had only weak relaxant activity on guinea pig trachea in vitro. Pirodomast is, therefore, a potential antiallergic agent that inhibits leukotriene (LT) release. Pirodomast inhibited tryptase proteolytic activity in-vitro. In experimental studies in vivo, pirodomast blocked antigen-induced immediate and late asthmatic responses in allergic sheep. Pirodomast inhibited antigen-induced airway hyperresponsiveness to both histamine and carbachol in allergic sheep. Pirodomast was being investigated for use in asthma and allergic rhinitis.

Pirnabine is the synthetic dibenzopyran drug. It was developed as anti-glaucoma drug.

Pentisomicin (Sch 21420) is semisynthetic aminoglycosides with marked antibacterial activity. Like many new aminoglycosides prepared by chemical modification or mutational biosynthesis, Pentisomicin was designed either to enhance potency of the parent compound and/or resist enzymatic inactivation. The activity of Pentisomicin was comparable to gentamicin, sisomicin, netilmicin, and tobramycin but greater than amikacin or kanamycin against S. aureus and most genera of Enterobacteriaceae.

Furcloprofen was developed as an analgesic agent with anti-inflammatory properties. Information about the current use of this compound is not available.

Pararosaniline pamoate (CI 403-A) was developed as an orally active drug for the treatment of Schistosoma japonicum infection. The clinical trial has shown that capsules were safe and effective; in addition, this drug was well tolerated with a minimum of side effects, which were mostly mild and transient and did not require interruption of treatment. Besides, pararosaniline pamoate was an inhibitor of E.histolytica Hsp90 (EhHsp90) with promising activity against the parasite Pararosaniline pamoate, that causes amebiasis worldwide. Information about the current use of this drug is not available.